Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 159
Filter
1.
Nat Commun ; 14(1): 8102, 2023 Dec 07.
Article in English | MEDLINE | ID: mdl-38062031

ABSTRACT

Clonal hematopoiesis (CH) is defined as a single hematopoietic stem/progenitor cell (HSPC) gaining selective advantage over a broader range of HSPCs. When linked to somatic mutations in myeloid malignancy-associated genes, such as TET2-mediated clonal hematopoiesis of indeterminate potential or CHIP, it represents increased risk for hematological malignancies and cardiovascular disease. IL1ß is elevated in patients with CHIP, however, its effect is not well understood. Here we show that IL1ß promotes expansion of pro-inflammatory monocytes/macrophages, coinciding with a failure in the demethylation of lymphoid and erythroid lineage associated enhancers and transcription factor binding sites, in a mouse model of CHIP with hematopoietic-cell-specific deletion of Tet2. DNA-methylation is significantly lost in wild type HSPCs upon IL1ß administration, which is resisted by Tet2-deficient HSPCs, and thus IL1ß enhances the self-renewing ability of Tet2-deficient HSPCs by upregulating genes associated with self-renewal and by resisting demethylation of transcription factor binding sites related to terminal differentiation. Using aged mouse models and human progenitors, we demonstrate that targeting IL1 signaling could represent an early intervention strategy in preleukemic disorders. In summary, our results show that Tet2 is an important mediator of an IL1ß-promoted epigenetic program to maintain the fine balance between self-renewal and lineage differentiation during hematopoiesis.


Subject(s)
Clonal Hematopoiesis , Dioxygenases , Mice , Animals , Humans , DNA-Binding Proteins/metabolism , Hematopoiesis/genetics , Hematopoietic Stem Cells/metabolism , Epigenesis, Genetic , Transcription Factors/genetics , Transcription Factors/metabolism , Dioxygenases/metabolism
2.
Sci Rep ; 8(1): 716, 2018 01 15.
Article in English | MEDLINE | ID: mdl-29335417

ABSTRACT

8000 years ago, prior to Neolithic agriculture, Europe was mostly a wooded continent. Since then, its forest cover has been progressively fragmented, so that today it covers less than half of Europe's land area, in many cases having been cleared to make way for fields and pasture-land. Establishing the origin of Europe's current, more open land-cover mosaic requires a long-term perspective, for which pollen analysis offers a key tool. In this study we utilise and compare three numerical approaches to transforming pollen data into past forest cover, drawing on >1000 14C-dated site records. All reconstructions highlight the different histories of the mixed temperate and the northern boreal forests, with the former declining progressively since ~6000 years ago, linked to forest clearance for agriculture in later prehistory (especially in northwest Europe) and early historic times (e.g. in north central Europe). In contrast, extensive human impact on the needle-leaf forests of northern Europe only becomes detectable in the last two millennia and has left a larger area of forest in place. Forest loss has been a dominant feature of Europe's landscape ecology in the second half of the current interglacial, with consequences for carbon cycling, ecosystem functioning and biodiversity.


Subject(s)
Biodiversity , Forests , Plant Dispersal , Plants/classification , Population Density , Europe , Fossils , Humans , Pollen , Radiometric Dating
3.
Genes Brain Behav ; 17(2): 149-157, 2018 02.
Article in English | MEDLINE | ID: mdl-28857482

ABSTRACT

The imprinted gene Cdkn1c is expressed exclusively from the maternally inherited allele as a consequences of epigenetic regulation. Cdkn1c exemplifies many of the functional characteristics of imprinted genes, playing a role in foetal growth and placental development. However, Cdkn1c also plays an important role in the brain, being key to the appropriate proliferation and differentiation of midbrain dopaminergic neurons. Using a transgenic model (Cdkn1cBACx1 ) with a twofold elevation in Cdkn1c expression that mimics loss-of-imprinting, we show that increased expression of Cdkn1c in the brain gives rise to neurobiological and behavioural changes indicative of a functionally altered dopaminergic system. Cdkn1cBACX1 mice displayed altered expression of dopamine system-related genes, increased tyrosine hydroxylase (Th) staining and increased tissue content of dopamine in the striatum. In addition, Cdkn1cBACx1 animals were hypersensitive to amphetamine as showed by c-fos expression in the nucleus accumbens. Cdkn1cBACX1 mice had significant changes in behaviours that are dependent on the mesolimbic dopaminergic system. Specifically, increased motivation for palatable food stuffs, as indexed on a progressive ratio task. In addition, Cdkn1cBACX1 mice displayed enhanced social dominance. These data show, for the first time, the consequence of elevated Cdkn1c expression on dopamine-related behaviours highlighting the importance of correct dosage of this imprinted gene in the brain. This work has significant relevance for deepening our understanding of the epigenetic factors that can shape neurobiology and behaviour.


Subject(s)
Cyclin-Dependent Kinase Inhibitor p57/genetics , Dopamine/pharmacology , Promoter Regions, Genetic/drug effects , Animals , Behavior, Animal , Brain/physiopathology , Dopaminergic Neurons/drug effects , Dopaminergic Neurons/metabolism , Genomic Imprinting/genetics , Mice, Inbred C57BL , Mice, Transgenic , Proto-Oncogene Proteins c-fos/genetics
4.
Eur J Clin Nutr ; 64(7): 669-77, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20485304

ABSTRACT

BACKGROUND: To evaluate whether a fermented dairy drink containing the probiotic strain Lactobacillus casei DN-114 001 could reduce the incidence of common infectious diseases (CIDs) and the change of behavior because of illness in children. SUBJECTS/METHODS: We conducted a double-blinded, randomized, placebo-controlled allocation concealment clinical trial in the Washington, DC metropolitan area. Participants were 638 children 3-6 years old in daycare/schools. The intervention was a fermented dairy drink containing a specific probiotic strain or matching placebo with no live cultures for 90 consecutive days. Two primary outcomes were assessed: incidence of CIDs and change of behavior because of illness (both assessed by parental report). RESULTS: The rate of change of behavior because of illness was similar among active and control groups. However, the incidence rate for CIDs in the active group (0.0782) is 19% lower than that of the control group (0.0986) (incidence rate ratio=0.81, 95% CI: 0.65, 099) P=0.046. CONCLUSIONS: Daily intake of a fermented dairy drink containing the probiotic strain L. casei DN-114 001 showed some promise in reducing overall incidence of illness, but was primarily driven by gastrointestinal infections and there were no differences in change of behavior.


Subject(s)
Communicable Disease Control , Gastrointestinal Diseases/prevention & control , Lacticaseibacillus casei , Probiotics/therapeutic use , Respiratory Tract Infections/prevention & control , Child , Child, Preschool , Communicable Diseases/epidemiology , Dairy Products , District of Columbia/epidemiology , Double-Blind Method , Female , Fermentation , Gastrointestinal Diseases/epidemiology , Humans , Incidence , Male , Respiratory Tract Infections/epidemiology
5.
Neuroscience ; 153(1): 162-74, 2008 Apr 22.
Article in English | MEDLINE | ID: mdl-18359573

ABSTRACT

The Na(+)-driven Cl-HCO(3) exchanger (NDCBE or SLC4A8) is a member of the solute carrier 4 (SLC4) family of HCO(3)(-) transporters, which includes products of 10 genes with similar sequences. Most SLC4 members play important roles in regulating intracellular pH (pH(i)). Physiological studies suggest that NDCBE is a major pH(i) regulator in at least hippocampal (HC) pyramidal neurons. We generated a polyclonal rabbit antibody directed against the first 18 residues of the cytoplasmic N terminus (Nt) of human NDCBE. By Western blotting, the antibody distinguishes NDCBE-as a purified Nt peptide or a full-length transporter (expressed in Xenopus oocytes)-from other Na(+)-coupled HCO(3)(-) transporters. By Western blotting, the antiserum recognizes an approximately 135-kDa band in several brain regions of adult mice: the cerebral cortex (CX), subcortex (SCX), cerebellum (CB), and HC. In CX, PNGase F treatment reduces the molecular weight to approximately 116 kDa. By immunocytochemistry, affinity-purified (AP) NDCBE antibody stains the plasma membrane of neuron cell bodies and processes of rat HC neurons in primary culture as well as freshly dissociated mouse HC neurons. The AP antibody does not detect substantial NDCBE levels in freshly dissociated HC astrocytes, or astrocytes in HC or CB sections. By immunohistochemistry, the AP antibody recognizes high levels of NDCBE in neurons of CX, HC (including pyramidal neurons in Cornu Ammonis (CA)1-3 and dentate gyrus), substantial nigra, medulla, cerebellum (especially Purkinje and granular cells), and the basolateral membrane of fetal choroid plexus. Thus, NDCBE is in a position to contribute substantially to pH(i) regulation in multiple CNS neurons.


Subject(s)
Brain/metabolism , Neurons/metabolism , Sodium-Bicarbonate Symporters/metabolism , Animals , Antibody Specificity , Brain/cytology , Cells, Cultured , Choroid Plexus/cytology , Choroid Plexus/metabolism , Female , Humans , Hydrogen-Ion Concentration , Immunohistochemistry/methods , Intracellular Fluid/metabolism , Mice , Rabbits , Rats , Sodium-Bicarbonate Symporters/chemistry , Sodium-Bicarbonate Symporters/genetics , Sodium-Bicarbonate Symporters/immunology , Sodium-Bicarbonate Symporters/isolation & purification
6.
Neuroscience ; 151(2): 374-85, 2008 Jan 24.
Article in English | MEDLINE | ID: mdl-18061361

ABSTRACT

NCBE (SLC4A10) is a member of the SLC4 family of bicarbonate transporters, several of which play important roles in intracellular-pH regulation and transepithelial HCO(3)(-) transport. Here we characterize a new antibody that was generated in rabbit against a fusion protein consisting of maltose-binding protein and the first 135 amino acids (aa) of the N-terminus of human NCBE. Western blotting--both of purified peptides representing the initial approximately 120 aa of the transporters and of full-length transporters expressed in Xenopus oocytes--demonstrated that the antibody is specific for NCBE versus the two most closely related proteins, NDCBE (SLC4A8) and NBCn1 (SLC4A7). Western blotting of tissue in four regions of adult mouse brain indicates that NCBE is expressed most abundantly in cerebral cortex (CX), cerebellum (CB) and hippocampus (HC), and less so in subcortex (SCX). NCBE protein was present in CX, CB, and HC microdissected to avoid choroid plexus. Immunocytochemistry shows that NCBE is present at the basolateral membrane of embryonic day 18 (E18) fetal and adult choroid plexus. NCBE protein is present by Western blot and immunocytochemistry in cultured and freshly dissociated HC neurons but not astrocytes. By Western blot, nearly all NCBE in mouse and rat brain is highly N-glycosylated (approximately 150 kDa). PNGase F reduces the molecular weight (MW) of natural NCBE in mouse brain or human NCBE expressed in oocytes to approximately the predicted MW of the unglycosylated protein. In oocytes, mutating any one of the three consensus N-glycosylation sites reduces glycosylation of the other two, and the triple mutant exhibits negligible functional expression.


Subject(s)
Antibodies/chemistry , Brain Chemistry/physiology , Chloride-Bicarbonate Antiporters/metabolism , Sodium-Bicarbonate Symporters/metabolism , Animals , Blotting, Western , Brain Chemistry/genetics , Cells, Cultured , Chloride-Bicarbonate Antiporters/chemistry , Genetic Vectors , Glycosylation , Green Fluorescent Proteins/genetics , Humans , Immunohistochemistry , Mice , Molecular Sequence Data , Molecular Weight , Mutagenesis, Site-Directed , Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase/chemistry , Rats , Recombinant Fusion Proteins/pharmacology , Reproducibility of Results , Sodium-Bicarbonate Symporters/chemistry , Species Specificity , Tissue Distribution , Xenopus laevis
7.
Ann N Y Acad Sci ; 1054: 155-68, 2005.
Article in English | MEDLINE | ID: mdl-16339661

ABSTRACT

Despite the availability of deferoxamine (DFO) for more than three decades, its rates of interaction with cellular iron pools in different tissues, and the effects of its pharmacokinetics on the interaction with plasma iron pools, remain incompletely understood. The positive charge of DFO, together with the negative resting potential in vertebrate cells, favors cellular uptake, whereas the low lipophilicity and high molecular weight counter this effect. The findings presented suggest a facilitated uptake of DFO into hepatocytes, being several hundred-fold faster than into red cells. Antibodies that selectively recognize ferrioxamine (FO) show that initial hepatocellular iron chelation is cytosolic, but later transposes to lysosomal and ultimately canalicular compartments. Strong FO staining is visible in myocytes within 4-8 h after commencing a subcutaneous DFO infusion, indicating effective chelation of myocyte iron. A methodology was developed to study the interaction of DFO and its metabolites with plasma iron pools by stabilizing DFO with aluminum ions, thereby preventing iron shuttling from non-transferrin-bound iron (NTBI) onto DFO after plasma collection. DFO removes only about a third of NTBI rapidly, and NTBI is rarely cleared completely. Increasing DFO dosing does not increase NTBI removal, but instead leads to a greater rebound in NTBI on cessation of intravenous infusion. Thus, intermittent infusions of high-dose DFO are less desirable than continuous infusions at low doses, particularly in high-risk patients. Here the benefits of continuous DFO on heart function occur before changes in T2*-visible storage iron, consistent with early removal of a toxic labile iron pool within myocytes.


Subject(s)
Deferoxamine/pharmacokinetics , Iron Chelating Agents/pharmacokinetics , Iron/metabolism , Animals , Body Fluid Compartments , Chelation Therapy , Chemical Phenomena , Chemistry, Physical , Deferoxamine/administration & dosage , Deferoxamine/pharmacology , Deferoxamine/therapeutic use , Drug Administration Routes , Drug Administration Schedule , Erythrocytes/drug effects , Erythrocytes/metabolism , Hepatocytes/drug effects , Hepatocytes/metabolism , Humans , Iron/blood , Iron Chelating Agents/administration & dosage , Iron Chelating Agents/pharmacology , Iron Chelating Agents/therapeutic use , Molecular Weight , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/metabolism , Organ Specificity , Solubility , Thalassemia/drug therapy , Thalassemia/metabolism
8.
Physiol Res ; 51 Suppl 1: S13-20, 2002.
Article in English | MEDLINE | ID: mdl-12479782

ABSTRACT

The functional aversive stimulus properties of several IP doses of (+/-)-amphetamine (1.25-10 mg.kg-1), 2-phenylethylamine (PEA, 2.5-10 mg.kg-1, following inhibition of monoamine oxidase with pargyline 50 mg.kg-1) and phenylethanolamine (6.25-50 mg.kg-1) were measured with the conditioned taste aversion (CTA) paradigm. A two-bottle choice procedure was used, water vs. 0.1 % saccharin with one conditioning trial and three retention trials. (+/-)-Amphetamine and phenylethanolamine induced a significant conditioned taste aversion but PEA did not. (+/-)-Amphetamine and PEA increased spontaneous locomotor activity but phenylethanolamine had no effects on this measure. Measurement of whole brain levels of these drugs revealed that the peak brain elevation of PEA occurred at approximately 10 min whereas the peak elevations of (+/-)-amphetamine and phenylethanolamine occurred at approximately 20 min. The present failure of PEA to elicit conditioned taste aversion learning is consistent with previous reports for this compound. The differential functional aversive stimulus effects of these three compounds are surprising since they exhibit similar discriminative stimulus properties and both (+/-)-amphetamine and PEA are self-administered by laboratory animals. The present data suggest that time to maximal brain concentrations following peripheral injection may be a determinant of the aversive stimulus properties of PEA derivatives.


Subject(s)
Avoidance Learning/drug effects , Conditioning, Psychological/drug effects , Phenethylamines/pharmacology , Taste , Amphetamine/pharmacokinetics , Amphetamine/pharmacology , Animals , Brain/metabolism , Male , Monoamine Oxidase Inhibitors/pharmacology , Motor Activity/drug effects , Osmolar Concentration , Phenethylamines/pharmacokinetics , Rats , Rats, Sprague-Dawley , Time Factors
9.
Arch Phys Med Rehabil ; 82(12): 1740-3, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11733893

ABSTRACT

A 49-year-old male recreational weight lifter suffered an isolated partial tear of the subscapularis muscle after minimal trauma. His history was atypical for development of a subscapularis tear, which made his case more difficult to evaluate and subsequently treat. His recovery was uncomplicated and was facilitated by a physical therapy program to enhance rotator cuff strength and proprioception. This report includes a brief review of the literature on the etiology and management of these tears. This case emphasizes the importance of an appropriate physical examination and judicious use of imaging techniques so that uncommon disorders, even those with unusual presentations, can be diagnosed and managed to obtain good outcomes.


Subject(s)
Rotator Cuff Injuries , Weight Lifting/injuries , Humans , Male , Middle Aged , Radiography , Rotator Cuff/diagnostic imaging , Wounds and Injuries/diagnosis , Wounds and Injuries/rehabilitation
10.
Caries Res ; 35(5): 331-7, 2001.
Article in English | MEDLINE | ID: mdl-11641568

ABSTRACT

The decline in prevalence of dental caries in some segments of the population has been attributed mainly to extensive exposure to fluoride. Over the past decades, the use of fluoridated products has increased. During the same period, the consumption of food preservatives such as benzoates and sorbates has also increased substantially. Benzoates, in vitro, possess antibacterial properties similar to those of fluoride and in combination with fluoride could affect caries development. In the present study we explored the effects of sodium benzoate and fluoride in combination and alone on dental caries in our animal model. The results showed a combination of benzoate and fluoride reduced caries activity more effectively in rodents fed a cariogenic diet ad libitum than fluoride alone (p = 0.038).


Subject(s)
Anti-Bacterial Agents/therapeutic use , Benzoates/therapeutic use , Cariostatic Agents/therapeutic use , Dental Caries/prevention & control , Fluorides/therapeutic use , Saliva/physiology , Animals , Anti-Bacterial Agents/administration & dosage , Benzoates/administration & dosage , Cariostatic Agents/administration & dosage , Colony Count, Microbial , Dental Caries/classification , Dental Caries/microbiology , Diet, Cariogenic , Dietary Sucrose/adverse effects , Disease Models, Animal , Drug Combinations , Drug Synergism , Female , Fluorides/administration & dosage , Food Preservatives/administration & dosage , Food Preservatives/therapeutic use , Linear Models , Rats , Rats, Sprague-Dawley , Sorbic Acid/administration & dosage , Sorbic Acid/therapeutic use , Statistics as Topic , Streptococcus mutans/drug effects , Streptococcus mutans/growth & development , Streptococcus sobrinus/drug effects , Streptococcus sobrinus/growth & development
11.
J Membr Biol ; 183(1): 25-32, 2001 Sep 01.
Article in English | MEDLINE | ID: mdl-11547349

ABSTRACT

Previous squid-axon studies identified a novel K/HCO3 cotransporter that is insensitive to disulfonic stilbene derivatives. This cotransporter presumably responds to intracellular alkali loads by moving K(+) and HCO(3)(-) out of the cell, tending to lower intracellular pH (pH(i)). With an inwardly directed K/HCO(3) gradient, the cotransporter mediates a net uptake of alkali (i.e., K(+) and HCO(3)(-) influx). Here we test the hypothesis that intracellular quaternary ammonium ions (QA(+)) inhibit the inwardly directed cotransporter by interacting at the intracellular K(+) site. We computed the equivalent HCO(3)(-) influx (J(HCO3)) mediated by the cotransporter from the rate of pH(i) increase, as measured with pH-sensitive microelectrodes. We dialyzed axons to pH(i) 8.0, using a dialysis fluid (DF) free of K(+), Na(+) and Cl(-). Our standard artificial seawater (ASW) also lacked Na(+), K(+) and Cl(-). After halting dialysis, we introduced an ASW containing 437 mm K(+) and 0.5% CO(2)/12 mm HCO(3)(-), which (i) caused membrane potential to become transiently very positive, and (ii) caused a rapid pHi decrease, due to CO(2) influx, followed by a slower plateau-phase pH(i) increase, due to inward cotransport of K(+) and HCO(3)(-). With no QA(+) in the DF, J(HCO3) was approximately 58 pmole cm(-2) sec(-1). With 400 mm tetraethylammonium (TEA(+)) in the DF, J(HCO3) was virtually zero. The apparent K(i) for intracellular TEA(+) was approximately 78 mm, more than two orders of magnitude greater than that obtained by others for inhibition of K(+) channels. Introducing 100 mm inhibitor into the DF reduced J(HCO3) to approximately 20 pmole cm(-2) sec(-1) for tetramethylammonium (TMA(+)), approximately 24 for TEA(+), approximately 10 for tetrapropylammonium (TPA(+)), and virtually zero for tetrabutylammonium (TBA(+)). The apparent K(i) value for TBA(+) is approximately 0.86 mm. The most potent inhibitor was phenyl-propyltetraethylammonium (PPTEA(+)), with an apparent K(i) of approximately 91 microm. Thus, trans-side quaternary ammonium ions inhibit K/HCO(3) influx in the potency sequence PPTEA(+) > TBA(+) > TPA(+) > TEA(+) congruent with TMA(+). The identification of inhibitors of the K/HCO(3) cotransporter, for which no inhibitors previously existed, will facilitate the study of this transporter.


Subject(s)
Axons/drug effects , Quaternary Ammonium Compounds/pharmacology , Sodium-Bicarbonate Symporters/antagonists & inhibitors , Animals , Axons/metabolism , Bicarbonates/metabolism , Bicarbonates/pharmacology , Decapodiformes , Dose-Response Relationship, Drug , Ganglionic Stimulants/pharmacology , Ions , Potassium/metabolism , Potassium/pharmacology , Potassium Channel Blockers/pharmacology , Tetraethylammonium/pharmacology
12.
J Neurochem ; 78(4): 727-35, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11520893

ABSTRACT

An endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, was found to induce apoptosis in human dopaminergic SH-SY5Y cells by step-wise activation of apoptotic cascade; collapse in mitochondrial membrane potential, DeltaPsim, activation of caspases, and fragmentation of DNA. Recently, accumulation of gylceraldehyde-3-phosphate dehydrogenase (GAPDH) in nuclei was proposed to play an important role in apoptosis. In this paper, involvement of GAPDH in apoptosis induced by N-methyl(R)salsolinol was studied. The isoquinoline reduced DeltaPsim within 3 h, as detected by a fluorescence indicator, JC-1, then after 16 h incubation, GAPDH accumulated in nuclei by detection with immunostaining. To clarify the role of GAPDH in apoptotic process, a stable cell line of Bcl-2 overexpressed SH-SY5Y cells was established. Overexpression of Bcl-2 prevented the decline in DeltaPsim and also apoptotic DNA damage induced by N-methyl(R)salsolinol. In Bcl-2 transfected cells, nuclear translocation of GAPDH was also completely suppressed. In addition, a novel antiparkinsonian drug, rasagiline, prevented nuclear accumulation of GAPDH induced by N-methyl(R)salsolinol in control cells. These results suggest that GAPDH may accumulate in nuclei as a consequence of signal transduction, which is antagonized by anti-apoptotic Bcl-2 protein family and rasagiline. The results are discussed in concern to intracellular mechanism underlying anti-apoptotic function of rasagiline analogues.


Subject(s)
Active Transport, Cell Nucleus/physiology , Apoptosis/drug effects , Cell Nucleus/enzymology , Glyceraldehyde-3-Phosphate Dehydrogenases/metabolism , Indans/pharmacology , Proto-Oncogene Proteins c-bcl-2/metabolism , Salsoline Alkaloids/pharmacology , Tetrahydroisoquinolines , Animals , Apoptosis/physiology , Cell Line , Humans , Immunoblotting , Immunohistochemistry , Indans/therapeutic use , Membrane Potentials/drug effects , Mitochondria/metabolism , Neuroprotective Agents/pharmacology , Neurotoxins/chemistry , Neurotoxins/pharmacology , Parkinson Disease/drug therapy , Proto-Oncogene Proteins c-bcl-2/genetics , Salsoline Alkaloids/chemistry , Signal Transduction , Transfection
13.
Drug Metab Dispos ; 29(8): 1156-61, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11454735

ABSTRACT

(R)-N-(2-Heptyl)-N-methyl-propargylamine (R-2HMP) and (R)-N-(2-heptyl)-propargylamine (R-2HPA) are analogs of R-deprenyl. R-Deprenyl, a selective monoamine oxidase B inhibitor, is a mechanism-based inactivator of purified CYP2B1. The aim of the present study was to determine whether R-2HMP and R-2HPA behaved like deprenyl with respect to inhibiting cytochrome P450 (CYP450) enzyme activity. The activities of CYP1A2 and CYP1A1 were assessed by measuring the deethylation of 7-ethoxyresorufin by liver microsomes obtained from control and beta-naphthoflavone-treated female Wistar rats, respectively. CYP2B1 activity was assessed by measuring depentylation of 7-pentoxyresorufin by liver microsomes obtained from phenobarbital-treated rats. The activity of CYP1A1 was unaffected by 100 microM concentrations of R-deprenyl, R-2HMP, or R-2HPA. In contrast, the activities of CYP1A2 and CYP2B1 were significantly decreased. In general, the percentage of CYP1A2 activity remaining in the presence of 100 microM of one of these propargylamines ranged from 45 to 56%, whereas 10% or less of CYP2B1 activity remained. No marked differences between the various propargylamines were observed. The IC(50) values for the inhibition of CYP2B1 activity by R-deprenyl, R-2HMP, and R-2HPA were found to be 2.6, 8.5, and 3.6 microM, respectively. The S-enantiomers of deprenyl, 2HMP, and 2HPA also inhibited the activity of microsomal CYP2B1. R-2HMP, R-2HPA, and S-2HPA were found to be mechanism-based inactivators of CYP2B1 activity. The inactivation constants k(inact) and K(I) were found to be as follows: R-deprenyl, 1.3 microM and 0.32 min(-1); R-2HMP, 0.8 microM and 0.08 min(-1); R-2HPA, 0.5 microM and 0.36 min(-1); and S-2HPA, 0.24 microM and 0.18 min(-1).


Subject(s)
Cytochrome P-450 CYP1A2 Inhibitors , Cytochrome P-450 CYP2B1/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Microsomes, Liver/enzymology , Pargyline/pharmacology , Propylamines/pharmacology , Animals , Cytochrome P-450 CYP1A1/antagonists & inhibitors , Female , Kinetics , Microsomes, Liver/drug effects , Monoamine Oxidase Inhibitors/pharmacology , Pargyline/analogs & derivatives , Rats , Rats, Wistar , Selegiline/pharmacology , Ultrafiltration
14.
J Neural Transm (Vienna) ; 108(1): 11-24, 2001.
Article in English | MEDLINE | ID: mdl-11261742

ABSTRACT

Endogenous N-methyl(R)salsolinol, which caused parkinsonism in rats by injection in the striatum, was found to induce apoptosis in dopaminergic neuroblastoma SH-SY5Y cells. After 12-h incubation with 500[microM N-methyl(R)salsolinol, almost all the cells died with apoptosis and necrotic cell death was negligible. N-Methyl(R)salsolinol was much more potent to induce apoptosis than the (S)-enantiomer. The mechanism of apoptosis was studied in relation to changes in mitochondrial membrane potential, deltapsi(m), using a fluorescent indicator, JC-1. Red fluorescence of J-aggregates representing hyperpolarized deltapsi(m) was found to decrease significantly within 60 min after incubation with N-methyl(R)salsolinol, but not by the (S)-enantiomer at the same concentration. It suggests that mitochondria may recognize the stereo-chemical structure of N-methyl(R) salsolinol. Aliphatic propargylamines, (R)-N-(2-heptyl)-N-methylpropargylamine and (R)-N-(2-heptyl)propargylamine, were found to prevent deltapsim loss and subsequent apoptosis induced by N-methyl(R)salsolinol. These results suggest that mitochondria play a key role in the induction of apoptosis by the neurotoxin and the prevention by aliphatic propargylamines.


Subject(s)
Alkynes/pharmacology , Apoptosis/drug effects , Monoamine Oxidase Inhibitors/pharmacology , Neuroprotective Agents/pharmacology , Neurotoxins/pharmacology , Parkinsonian Disorders/prevention & control , Salsoline Alkaloids/pharmacology , Tetrahydroisoquinolines , Tumor Cells, Cultured/drug effects , Apoptosis/physiology , Dopamine/metabolism , Drug Interactions/physiology , Fluorescent Dyes , Humans , Membrane Potentials/drug effects , Membrane Potentials/physiology , Mitochondria/drug effects , Mitochondria/metabolism , Mitochondria/pathology , Neuroblastoma , Neurons/drug effects , Neurons/metabolism , Neurons/pathology , Parkinsonian Disorders/chemically induced , Parkinsonian Disorders/physiopathology , Signal Transduction/drug effects , Signal Transduction/physiology , Stereoisomerism , Substantia Nigra/drug effects , Substantia Nigra/metabolism , Substantia Nigra/physiopathology , Tumor Cells, Cultured/cytology , Tumor Cells, Cultured/metabolism
15.
Stat Med ; 20(7): 1097-111, 2001 Apr 15.
Article in English | MEDLINE | ID: mdl-11276039

ABSTRACT

A life history can be regarded as a random process that evolves with age through various states of health before terminating with absorption into the state of death. Health expectancies are the occupation times of the non-absorbing states and their estimation is of interest. A continuing major problem has been the lack of satisfactory longitudinal data on which to base estimates and as a result standard inferential techniques may not be relevant. Supposing only cross-sectional data available, we propose a method that is generally applicable and first estimates a logistic parametrization of the probabilities of the various states. A large sample approximation is obtained for the distribution of age specific log (odds). Parameters are estimated by weighted least squares, and this in turn leads to estimates of cohort health expectancies. A result of Liang and Zeger is used to find standard errors. The method is illustrated by application to Australian data from the health surveys of 1981, 1988 and 1993.


Subject(s)
Cohort Studies , Cross-Sectional Studies , Disability Evaluation , Disease-Free Survival , Health Surveys , Aged , Aged, 80 and over , Australia , Bias , Female , Geriatric Assessment/statistics & numerical data , Humans , Male , Middle Aged , Probability
16.
Biochem Pharmacol ; 61(6): 741-8, 2001 Mar 15.
Article in English | MEDLINE | ID: mdl-11266660

ABSTRACT

Semicarbazide-sensitive amine oxidase (SSAO) catalyzes the deamination of methylamine and aminoacetone to produce toxic aldehydes, i.e. formaldehyde and methylglyoxal, as well as hydrogen peroxide and ammonia. An increase of SSAO activity was detected by different laboratories in patients suffering from vascular disorders, i.e. diabetes and myocardial infarction. The enzyme has been suggested to play a role in vascular endothelial damage and atherogenesis. To date, there are no selective SSAO inhibitors. In the present study, 2-bromoethylamine (2-BrEA) was found to be a highly effective and selective inhibitor of SSAO obtained from different sources. The inhibition was irreversible and time dependent. It was competitive when the enzyme was not preincubated with the inhibitor, but became noncompetitive after incubation of the enzyme with 2-BrEA. The aldehyde trapping agent o-phenylenediamine was capable of preventing 2-BrEA-induced inhibition of SSAO activity. An aldehyde product was detected to be an initial product of 2-BrEA after it was incubated with SSAO. The inhibition, therefore, is mechanism-based. The SSAO inhibitory effects of eight structural analogues of 2-BrEA were assessed. It was concluded that a bromine atom at the beta position is quite important for exerting high potency of SSAO inhibition. The inhibition of SSAO activity by 2-BrEA was also demonstrated in vivo. It increased the urinary excretion of methylamine, an endogenous substrate for SSAO, in mice. 2-BrEA can be employed as a very useful tool in the investigation of SSAO.


Subject(s)
Amine Oxidase (Copper-Containing)/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Ethylamines/pharmacology , Amine Oxidase (Copper-Containing)/metabolism , Analysis of Variance , Animals , Chromatography, High Pressure Liquid , Ethylamines/chemistry , Male , Methylamines/urine , Mice , Monoamine Oxidase/drug effects , Monoamine Oxidase/metabolism , Structure-Activity Relationship
17.
Blood ; 95(4): 1229-36, 2000 Feb 15.
Article in English | MEDLINE | ID: mdl-10666195

ABSTRACT

The optimal regimen of intravenous deferoxamine for iron overload in high-risk homozygous beta-thalassemia is unknown because only short-term follow-up has been described in small patient groups. We report the outcome over a 16-year period of a continuous 24-hour deferoxamine regimen, with dose adjustment for serum ferritin, delivered via 25 indwelling intravenous lines for 17 patients. Treatment indications were cardiac arrhythmias, left ventricular dysfunction, gross iron overload, and intolerability of subcutaneous deferoxamine. Cardiac arrhythmias were reversed in 6 of 6 patients, and the left ventricular ejection fraction improved in 7 of 9 patients from a mean (+/- SEM) of 36 +/- 2% to 49 +/- 3% (P =.002, n = 9). The serum ferritin fell in a biphasic manner from a pretherapy mean of 6281 +/- 562 microg/L to 3736 +/- 466 microg/L (P =.001), falling rapidly and proportionally to the pretreatment ferritin (r(2) = 0.99) for values >3000 microg/L but falling less rapidly below this value (at 133 +/- 22 microg/L/mo). The principal catheter-related complications were infection and thromboembolism (1. 15 and 0.48 per 1000 catheter days, respectively), rates similar to other patient groups. Only one case of reversible deferoxamine toxicity was observed (retinal) when the therapeutic index was briefly exceeded. An actuarial survival of 61% at 13 years with no treatment-related mortality provides evidence of the value of this protocol. (Blood. 2000;95:1229-1236)


Subject(s)
Chelating Agents/therapeutic use , Deferoxamine/administration & dosage , Deferoxamine/therapeutic use , beta-Thalassemia/drug therapy , Actuarial Analysis , Adolescent , Adult , Catheters, Indwelling , Chelating Agents/administration & dosage , Female , Ferritins/blood , Follow-Up Studies , Humans , Infusions, Intravenous , Male , Regression Analysis , Survival Analysis , Time Factors , Treatment Outcome , beta-Thalassemia/blood , beta-Thalassemia/mortality
18.
Drug Metab Dispos ; 28(2): 147-54, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10640511

ABSTRACT

(R)-N-(2-Heptyl)-N-methylpropargylamine (R-2HMP) is a monoamine oxidase inhibitor and putative antiapoptotic agent analogous to (R)-deprenyl. In the rat, the major amine metabolites of R-2HMP have been identified as (R)-N-2-heptylmethylamine (R-2HMA), (R)-N-2-heptylpropargylamine (R-2HPA), and (R)-2-heptylamine (R-2HA). After R-2HMP was administered s.c. to male Wistar rats, it was observed that the greatest concentration was of the original drug followed in decreasing order by R-2HMA, R-2HPA, and R-2HA in brain, liver, and plasma at all times after administration. The greatest concentrations of the three metabolites were found in brain followed by liver and plasma, and the peak concentrations occurred between 15 and 30 min after administration. After oral administration, the liver contained the greatest concentrations of drug and metabolites, and, again, the peak concentrations occurred at about 15 min. In all cases, depropargylation appears to occur at a faster rate than demethylation. After s.c. administration, R-2HMP and its metabolites exhibited biexponential redistribution and elimination losses. Half-lives of the compounds in brain for the redistribution phase were: R-2HMP, 10 min; R-2HMA, 11 min; R-2HPA, 16 min; and R-2HA, 15 min.


Subject(s)
Alkynes/pharmacokinetics , Apoptosis/drug effects , Monoamine Oxidase Inhibitors/pharmacokinetics , Administration, Oral , Algorithms , Alkynes/administration & dosage , Alkynes/pharmacology , Amines/blood , Amines/metabolism , Amines/urine , Animals , Biotransformation , Brain/metabolism , Deuterium , Gas Chromatography-Mass Spectrometry , Injections, Subcutaneous , Isotope Labeling , Liver/metabolism , Male , Monoamine Oxidase Inhibitors/administration & dosage , Monoamine Oxidase Inhibitors/pharmacology , Rats , Rats, Wistar
19.
Nutr Cancer ; 38(2): 281-6, 2000.
Article in English | MEDLINE | ID: mdl-11525607

ABSTRACT

In previous studies, decreased growth of tumor cells by vitamin B-6 treatment has been attributed to modulation of steroid hormone action. Therefore, the growth-inhibiting properties of pyridoxal (PL) supplementation were studied in estrogen receptor-positive, MCF-7 and T-47D, and estrogen receptor-negative, BT-20, breast cancer cell lines. Cell counting and [3H]thymidine incorporation into DNA were used to assess growth, and analysis of pS2 expression was used to determine whether PL supplementation affected estrogen action. Treatment with 100 or 300 mM PL resulted in dose-dependent decreases in total cell numbers in the absence (26-85% and 72-98%, respectively) and presence (38-42% and 88-98%, respectively) of estradiol in all cell lines studied compared with control cells cultured without PL supplementation. Similar decreases in DNA synthesis were observed in response to PL supplementation. Incorporation of [3H]thymidine into DNA of cells cultured with 100 or 300 microM PL was decreased by 30-90% and 96-99%, respectively, in the absence and by 32-40% and 82-99%, respectively, in the presence of estradiol. Northern analysis showed that expression of the estrogen-sensitive gene pS2 was not affected by either concentration of PL. These results indicate that PL supplementation regulates breast cancer cell growth in vitro via a mechanism that appears to be steroid independent.


Subject(s)
Carcinoma/pathology , DNA, Neoplasm/biosynthesis , Dietary Supplements , Mammary Neoplasms, Animal/pathology , Neoplasms, Hormone-Dependent/pathology , Proteins/genetics , Pyridoxal/administration & dosage , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacology , Carcinoma/metabolism , Cell Division/drug effects , DNA, Neoplasm/drug effects , Dose-Response Relationship, Drug , Estradiol/metabolism , Female , Humans , Mammary Neoplasms, Animal/metabolism , Neoplasms, Hormone-Dependent/metabolism , Protein Biosynthesis , Proteins/drug effects , Pyridoxal/pharmacology , RNA, Messenger/metabolism , Receptors, Estrogen/metabolism , Trefoil Factor-1 , Tumor Cells, Cultured , Tumor Suppressor Proteins
20.
J Nurs Care Qual ; 13(6): 11-24, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10476621

ABSTRACT

This descriptive, correlational study examines relationships between (1) individual patient and nurse characteristics and (2) patient satisfaction with triage nursing care, patient satisfaction with the triage nurse, and patient's intention to return to a specific Emergency Department. The convenience sample consisted of Urgent/Delayed patients (N = 378) triaged in an urban academic medical center, a public hospital in a small city, and a Catholic hospital in a small city. Analysis of variance revealed significantly higher levels of patient satisfaction at the academic medical center, whereas higher levels of intent to return were reported by subjects from the Catholic-affiliated hospital. Educational preparation of the triage nurse was identified as a significant predictor of both patient satisfaction with triage nursing care and loyalty to a specific.


Subject(s)
Emergency Nursing/standards , Patient Satisfaction/statistics & numerical data , Triage/standards , Adult , Analysis of Variance , Emergency Service, Hospital/standards , Female , Humans , Male , Middle Aged , Nurse-Patient Relations , Regression Analysis , Southeastern United States , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...